Mannatech, Inc. — FY2015 Form 10-K
Reporting period: Fiscal year ended December 31, 2015; comparisons are with FY2014. This filing reports annual results, not standalone fourth-quarter results. Mannatech develops and sells wellness, nutritional supplement, skin-care and weight-management products through network marketing in 25 countries. It operates as one reportable segment and had about 219,000 active associate and member positions, down from 230,000 in 2014.
Financial performance
| Metric | FY2015 | FY2014 | Change |
|---|---|---|---|
| Net sales | $180.3 million | $190.1 million | Down 5.2% |
| Gross profit / margin | $146.2 million / 81.1% | $151.7 million / 79.8% | Profit down 3.7%; margin up 1.3 percentage points |
| Operating income / margin | $12.1 million / 6.7% | $12.7 million / 6.7% | Down 4.7% |
| Net income | $5.8 million | $6.5 million | Down 10.1% |
| Diluted EPS | $2.14 | $2.40 | Down 10.8% |
| Cash from operations | $4.4 million | $9.4 million | Down $5.0 million |
Operating expenses fell 3.6% to $134.0 million, but expenses rose as a share of sales to 74.3% from 73.1%. Commissions and incentives were $73.0 million (40.5% of sales), compared with $75.2 million (39.6%) in 2014. The effective tax rate declined to 28.9% from 33.9%. Foreign-exchange transaction losses increased to $4.2 million from $3.0 million.
Sales trends and material year-over-year changes
- Reported sales declined in all regions: North America fell 9.3% to $73.3 million; Asia/Pacific fell 1.1% to $91.4 million; EMEA fell 7.7% to $15.6 million.
- Unfavorable currency translation reduced reported sales by $11.8 million. On a constant-dollar basis, sales increased 1.1% to $192.1 million; constant-dollar results are a non-GAAP measure.
- Product sales fell 7.9% to $143.1 million, reflecting 3.7% fewer orders and a 6.6% decline in average order value ($155 versus $166). Pack sales rose 14.0% to $31.7 million, while other sales fell 21.4% to $5.5 million.
- Management attributed comparability in part to the normalization of the 2014 launch of Uth skin-care products and the loyalty program. Uth sales were $6.3 million in 2015 versus $13.8 million in 2014. Loyalty-program accounting contributed $5.8 million more recognized revenue in 2015 than in 2014.
- Five named product lines accounted for 50.4% of sales, down from 56.6% in 2014. Advanced Ambrotose alone contributed 32.7% of sales. Uth revenue fell to $5.4 million from $13.4 million.
Cash, liquidity and obligations
Cash and cash equivalents were $32.0 million at year-end, up from $28.0 million. Working capital increased to $23.6 million from $16.4 million. Total assets were $68.6 million and shareholders’ equity was $38.6 million. Restricted cash totaled approximately $8.1 million. Management said existing liquidity and operating cash flows should fund normal operations for the next 12 months, while noting that this depends on sustaining or improving revenue relative to expenses.
Year-end notes payable were $1.8 million, including $0.7 million current; capital-lease obligations totaled $1.1 million. Investing activities used $2.0 million, primarily for technology and leasehold improvements. Contractual commitments and obligations totaled $16.3 million, including $5.0 million of 2016 purchase commitments and $4.4 million of operating-lease payments. The company reported no off-balance-sheet arrangements and no dividends; dividends have been suspended since 2009.
Outlook, risks and unusual items
- Management expects operating cash flows to support normal business needs and possible international expansion, but gave no quantified revenue or earnings guidance. Colombia operations launched in the first quarter of 2016.
- Key risks include reliance on independent associates and network-marketing leaders, declining active positions, intense competition, regulatory scrutiny of product and income claims, foreign-currency exposure, and dependence on third-party manufacturers. Arabinogalactan, used in Ambrotose, had no identified alternative supplier.
- Patent protection for some Ambrotose technology expires beginning in late 2017; the company is pursuing additional protection. Product concentration, especially Advanced Ambrotose, makes sales vulnerable to a downturn in a small number of products.
- Pending matters include a Texas contract claim seeking more than $1 million; a Korean customs assessment of $1.0 million, which the company has accrued and is challenging; arbitration against founder Samuel Caster and Wonder Enterprises, with company-estimated damages of $0.5–$3.5 million; and ongoing trademark oppositions concerning Uth. Outcomes and potential liabilities for several matters were not estimable in the filing. A patent injunction against Wellness Quest was stayed during appeal; a separate patent case against RBC was settled with a permanent injunction.
- Related-party disclosures include $0.9 million in 2015 donations to the M5M Foundation, whose board includes company directors, officers or family members, and approximately $3.2 million in commissions and incentives paid to director Ray Robbins and family members.
- Management reported effective disclosure controls and internal control over financial reporting. The independent auditor issued an unqualified opinion on the financial statements.
Important facts for investors to verify
- Whether the decline in reported sales stabilizes, particularly in North America, and whether constant-dollar growth persists after currency and loyalty-program effects.
- Associate and member retention, order frequency, average order value, and the company’s ability to reduce reliance on Advanced Ambrotose and other concentrated products.
- Whether operating cash flow recovers from its decline and remains sufficient for operations and contractual commitments.
- Developments and potential financial effects of the pending litigation, arbitration, customs dispute, and trademark proceedings.
- Foreign-exchange movements, tax-audit outcomes, product regulatory requirements, and the availability of key ingredients and contract manufacturing capacity.